FOSTER CITY, Calif.--(BUSINESS WIRE)--Nov. 4, 2005--Applied Biosystems Group (NYSE:ABI), an Applera Corporation business, announced today that the arbitrator in an arbitration proceeding(1) filed by Amersham Biosciences, now GE Healthcare, had issued his decision in a matter involving the interpretation of a license agreement relating to DNA sequencing reagents and kits. Amersham had alleged, among other things, that Applied Biosystems had underpaid royalties under the license agreement. The arbitrator awarded Amersham past damages based on an increase in royalty rates for certain DNA sequencing enzymes and kits that contain those enzymes, plus interest, fees, and costs in an amount to be determined. As a result, Applied Biosystems will record a pre-tax adjustment of approximately $20.4 million to its previously-reported first quarter fiscal 2006 results. This adjustment will be reflected in Applera Corporation’s Form 10-Q for the period ending September 30, 2005, to be filed on or before November 9, 2005.